Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC

作者：Omar Elghawy, Adam Barsouk, Jonathan H. Sussman, Benjamin Aaron Bleiberg, Lauren Reed-Guy, Christopher D’Avella, Aditi Singh, Christine Ciunci, Kyle Robinson, John A. Kosteva, Corey J. Langer, Roger B. Cohen, Charu Aggarwal, Melina E. Marmarelis, Lova Sun · 发表于：JTO Clinical and Research Reports · 年份：2025 · DOI：10.1016/j.jtocrr.2025.100851 · 被引用次数：2 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies、Multiple and Secondary Primary Cancers

Background: Limited data are available on late immune-related adverse events (IRAEs) in patients with metastatic NSCLC receiving immunotherapy (ICI) beyond 2 years. Methods: A single-institution retrospective analysis including patients who received longer than 2 years of ICI therapy for metastatic NSCLC between 2012 and 2023 was performed. Late IRAEs were defined as those occurring longer than 2 years after initiation of ICI therapy. The association of late IRAE with OS and PFS was assessed using an extended Cox regression with late IRAE modeled as a time-varying covariate. Results: = 0.020). Late IRAE occurrence was not associated with median progression-free survival or median overall survival. Conclusions: In patients receiving extended-duration ICI beyond 2 years, late IRAEs were common and often occurred in patients without previous history of IRAE. These findings support consideration of ICI discontinuation at 2 years.